申请人:ALS Therapy Development Institute
公开号:US20200405689A1
公开(公告)日:2020-12-31
Methods are disclosed for treating neurodegenerative disorders, such as ALS and FTD by using an effective amount of a type I protein arginine methyltransferase (Type I PRMT) inhibitor to decrease cellular toxicity caused by dipeptide repeat proteins (DRPs).